Enjoy complimentary customisation on priority with our Enterprise License!
The analyst at Technavio predicts that the global musculoskeletal disorders therapeutics market will grow progressively and will post a modest CAGR of approximately 4% by 2020. One of the major factors that will drive market growth is the growing unmet medical needs in the global musculoskeletal disorders market. The unavailability of a cure for psoriatic arthritis will induce researchers to develop drugs that increase bone density, replace lost bone, and rebuild bone strength. Furthermore, to gain a competitive advantage, vendors will have to develop cost-competitive drugs with ease of administration that promotes bone building efficiently. For instance, Pfizer recently launched bazedoxifene and obtained US FDA approval for bazedoxifene as part of the combination drug Duavee in the prevention of postmenopausal osteoporosis. The lack of proper treatments and biologic drugs with severe side-effects will create an opportunity for vendors to develop therapies that have better efficacy and safety profiles.
According to the musculoskeletal disorders therapeutics market forecast, the Americas will dominate the market accounting for approximately 52% of the total market share. Higher uptake of existing biologic drugs to treat the condition, the launch of new biologics, and expanded access to medical care due to healthcare issues are factors that will drive the prospects for market growth. In addition, essential health-care benefits provided by employer-sponsored health insurance plans and increasing vendor investments in innovative and cost-effective drugs will also help the Americas to lead the market during the forecast period.
There is intense competition in the market and few key vendors lead the market with innovative product launches that counter the side-effects of biologic drugs, partnerships that help the research and developments of new medicines, and merger and acquisitions to introduce cost-effective drugs that have a wider customer reach.
Key vendors in the market are
Other prominent vendors in the market are 3SBio, AB Sciences, AbGenomics International, Ablynx, Adheron, Akron Molecules, Alder BioPharmaceuticals, Amgen Astellas BioPharma, Ampio Pharmaceuticals, Antares Medical Services, Astellas, AstraZeneca, Baxter, Biocad, Bioiberica, Boehringer Ingelheim, Bone Therapeutics, Can-Fite BioPharma, Celgene Corporation, Celltrion, Cellular Biomedicine, Cerapedics, ChemoCentryx, Chugai Pharmaceutical, Coherus Biosciences, Daiichi Sankyo, Dong-A ST, Edding Pharm, Eisai, Epirus, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gedeon Richter, Gilead Sciences, GlaxoSmithKline, Histogenics, IBSA Institut Biochimique, iCeutica, Iltoo Pharma, Incyte Corporation, Innovative Med Concepts, Iroko Pharmaceuticals, ISTO Technologies, KaloBios Pharmaceuticals, KAN Research Institute, Kang Stem Biotech, Kitov Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, MEDIPOST, Medivir, Merck, Mereo, Mesoblast, MOCHIDA PHARMACEUTICAL, MorphoSys, Morphotek, Mycenax, Neomed Institute, Novartis, Omeros Corporation, OrthoTrophix, Osteologix, OxyPharma, PFEnex, Philogen, PhytoHealth Corporation, Plexxikon, PLx Pharma, Protalex, Proximagen Limited, Radius Health, Regeneron Pharmaceuticals, Samsung Bioepis, Samumed, Sandoz, Sanofi, SantoSolve AS, Steminent Biotherapeutics, Stempeutics Research, Taisho Pharmaceutical, Taiwan Liposome Company, Takeda, Tarsa Therapeutics, Techfields Pharma, Tetec , TheraMAB, TiGenix, TissueGene, Tonix Pharmaceuticals, Translational Biosciences, UCB, Vericel, Vertex Pharmaceuticals, Vitaeris, Winston Laboratories, and Zosano Pharma Corporation.
During 2015, rheumatoid arthritis dominated the market by accounting for approximately 52% of the total market share. It is a chronic inflammatory autoimmune disease, and the symptoms appear slowly with mild pain around the joints coupled with stiffness and fatigue. This condition is most common in people within the age group of 30 to 60 years.
During 2015, the biologics molecule segment dominated the market, accounting for around 82% of the total market share. Biologics have a complex structure that does not allow easy identification or characterization and are mostly thermo-labile and susceptible to microbial contamination.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
PART 07: Market segmentation by disease type
PART 08: Global rheumatoid arthritis drugs market
PART 09: Global osteoarthritis drugs market
PART 10: Global osteoporosis drugs market
PART 11: Global ankylosing spondylitis drugs market
PART 12: Global psoriatic arthritis drugs market
PART 13: Global fibromyalgia drugs market
PART 14: Market segmentation by type of molecule
PART 15: Market segmentation by route of administration
PART 16: Geographical segmentation
PART 17: Market drivers
PART 18: Impact of drivers
PART 19: Market challenges
PART 20: Impact of drivers and challenges
PART 21: Market trends
PART 22: Vendor landscape
PART 23: Key vendor analysis
PART 24: Appendix
PART 25: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.